Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of bevacizumab and sunitinib in
treating patients with solid tumors. Monoclonal antibodies, such as bevacizumab, can block
tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
Others find tumor cells and help kill them or carry tumor-killing substances to them.
Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Bevacizumab and sunitinib may also stop the growth of tumor cells by blocking blood
flow to the tumor. Giving bevacizumab together with sunitinib may kill more tumor cells.